Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma.

Cancer Res Commun · 2025 · PMC12062949 · PMID 40299780

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In patients heavily pretreated with advanced/metastatic non–small cell lung cancer, phase III trial data showed improved PFS and a trend toward improved OS but did not reach statistical significance ( 23 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.